{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:55:17Z","timestamp":1778046917512,"version":"3.51.4"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"25","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,11,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Tamoxifen citrate is a very prevalent drug marketed under several trade names\nlike Apo-Tamox, Nolvadex, Tamec, Tamizam, and Tamoplex. This molecule is approved by the FDA\nfor breast cancer treatment. Some studies have shown that tamoxifen has anti-tuberculosis and antiparasitic\nactivities. Like any drug, tamoxifen possesses side effects, more or less dangerous.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>Basically, this work is a comparative study that aims to: primarily compare the antimicrobial and\nantitumor activities of tamoxifen and a newly synthesized tamoxifen analog; and to determine the molecule\nwith lesser side effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Three groups of mice were injected with tamoxifen citrate and compound 2(1,1-bis[4-(3-\ndimethylaminopropoxy)phenyl]-2-phenyl-but-1-ene dihydrochloride) at doses corresponding to C1\n(1\/10), C2 (1\/50), and C3 (1\/100) to compound 2 lethal dose (LD50 = 75 mg\/kg) administered to adult\nmice. A group of noninjected mice served as a study control.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Experimental results suggest that compound 2 has better antitumor and antimicrobial activity\nthan tamoxifen citrate besides its lower toxicity effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The results obtained from the present study confirmed the antitumor and antimicrobial\neffect of tamoxifen citrate and its hematological side effects. Compound 2 seems to be more effective\nthan tamoxifen citrate for antitumor and antimicrobial treatment while having less hematological side\neffects and less disruption of the blood biochemical parameters. These findings encourage us to perform\nfurther studies on compound 2 and test it for other therapeutic uses for which tamoxifen was found effective.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200819145526","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T08:15:12Z","timestamp":1597911312000},"page":"2281-2288","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antimicrobial, Antitumor and Side Effects Assessment of a Newly Synthesized Tamoxifen Analog"],"prefix":"10.2174","volume":"20","author":[{"given":"Fatma","family":"Abdmouleh","sequence":"first","affiliation":[{"name":"Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"El Arbi","sequence":"additional","affiliation":[{"name":"Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajer Ben","family":"Saad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Sfax, Laboratory of Pharmacology UR\/12 ES-13, 3029 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Jellali","sequence":"additional","affiliation":[{"name":"Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emna","family":"Ketata","sequence":"additional","affiliation":[{"name":"Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtissem Ben","family":"Amara","sequence":"additional","affiliation":[{"name":"Higher Institute of Biotechnology of Sfax, University of Sfax, Route de Sokra km 4, 3000 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pigeon","sequence":"additional","affiliation":[{"name":"Sorbonne Universite, UMR 8232 CNRS, IPCM, 4 place Jussieu, F-75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanen Ben","family":"Hassen","sequence":"additional","affiliation":[{"name":"Higher Institute of Biotechnology of Sfax, University of Sfax, Route de Sokra km 4, 3000 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siden","family":"Top","sequence":"additional","affiliation":[{"name":"Sorbonne Universite, UMR 8232 CNRS, IPCM, 4 place Jussieu, F-75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Jaouen","sequence":"additional","affiliation":[{"name":"Sorbonne Universite, UMR 8232 CNRS, IPCM, 4 place Jussieu, F-75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riadh","family":"Hammami","sequence":"additional","affiliation":[{"name":"School of Nutrition Sciences, University of Ottawa, Ottawa, K1N 7 K4, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamdouh Ben","family":"Ali","sequence":"additional","affiliation":[{"name":"Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish Kumar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Departemt of Pharmaceutical Chemistry, Sri Sai College of Pharmacy, Badhani, Pathankot-145001, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"Boucher H.W.","year":"2009","unstructured":"Boucher H.W.; Talbot G.H.; Bradley J.S.; Edwards J.E.; Gilbert D.; Rice L.B.; Scheld M.; Spellberg B.; Bartlett J.; Bad bugs, no drugs: no eskape! an update from the infectious diseases society of America. Clin Infect Dis 2009,48(1),1-12","journal-title":"Clin Infect Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4137\/PMC.S14459","volume":"6","author":"Fair R.J.","year":"2014","unstructured":"Fair R.J.; Tor Y.; Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem 2014,6,25-64","journal-title":"Perspect Medicin Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"v","DOI":"10.1016\/j.coviro.2015.08.009","volume":"14","author":"von Brunn A.","year":"2015","unstructured":"von Brunn A.; Editorial overview: Engineering for viral resistance. Curr Opin Virol 2015,14,v-vii","journal-title":"Curr Opin Virol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/cancers8030035","volume":"8","author":"El-Tanani M.","year":"2016","unstructured":"El-Tanani M.; Dakir H.; Raynor B.; Morgan R.; Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers (Basel) 2016,8(3),35","journal-title":"Cancers (Basel)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"42740","DOI":"10.18632\/oncotarget.8600","volume":"7","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Li Q.; Zhou L.; Xie N.; Nice E.C.; Zhang H.; Huang C.; Lei Y.; Cancer drug resistance: redox resetting renders a way. Oncotarget 2016,7(27),42740-42761","journal-title":"Oncotarget"},{"key":"ref=6","year":"2014","unstructured":"Antimicrobial resistance: global report on surveillance WHO2014","journal-title":"Antimicrobial resistance: global report on surveillance"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrd3975","volume":"12","author":"Lewis K.","year":"2013","unstructured":"Lewis K.; Platforms for antibiotic discovery. Nat Rev Drug Discov 2013,12(5),371-387","journal-title":"Nat Rev Drug Discov"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1086\/652237","volume":"50","year":"2010","unstructured":"The 10 x \u201920 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis Infectious Diseases Society of America2010,50(8),1081-1083","journal-title":"Clin Infect Dis"},{"key":"ref=9","first-page":"101","author":"Maximov P.Y.","year":"2013","unstructured":"Maximov P.Y.; McDaniel R.E.; Jordan V.C.;  Tamoxifen Pioneering Medicine in Breast Cancer 2013,101-114","journal-title":"Tamoxifen Pioneering Medicine in Breast Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrd1031","volume":"2","author":"Jordan V.C.","year":"2003","unstructured":"Jordan V.C.; Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003,2(3),205-213","journal-title":"Nat Rev Drug Discov"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.6-1-4","volume":"6","author":"Cohen M.H.","year":"2001","unstructured":"Cohen M.H.; Hirschfeld S.; Flamm Honig S.; Ibrahim A.; Johnson J.R.; O\u2019Leary J.J.; White R.M.; Williams G.A.; Pazdur R.; Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001,6(1),4-11","journal-title":"Oncologist"},{"key":"ref=12","year":"1998","unstructured":"(tamoxifen citrate) prescribing information  FDA. Nolvadex 1998","journal-title":"(tamoxifen citrate) prescribing information"},{"key":"ref=13","author":"Purvis J.","year":"2002","unstructured":"Purvis J.;  Dear doctor letter regarding warning information on serious or fatal adverse effects among women receiving tamoxifen for risk reduction 2002","journal-title":"Dear doctor letter regarding warning information on serious or fatal adverse effects among women receiving tamoxifen for risk reduction"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","volume":"339","author":"Osborne C.K.","year":"1998","unstructured":"Osborne C.K.; Osborne C.K.; Tamoxifen in the treatment of breast cancer. N Engl J Med 1998,339(22),1609-1618","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"Fisher B.","year":"2005","unstructured":"Fisher B.; Costantino J.P.; Wickerham D.L.; Cecchini R.S.; Cronin W.M.; Robidoux A.; Bevers T.B.; Kavanah M.T.; Atkins J.N.; Margolese R.G.; Runowicz C.D.; James J.M.; Ford L.G.; Wolmark N.; Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project p-1 study. J Natl Cancer Inst 2005,97(22),1652-1662","journal-title":"J Natl Cancer Inst"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"946","DOI":"10.4014\/jmb.1412.12023","volume":"25","author":"Jang W.S.","year":"2015","unstructured":"Jang W.S.; Kim S.; Podder B.; Jyoti M.A.; Nam K-W.; Lee B-E.; Song H-Y.; Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage mycobacterium tuberculosis. J Microbiol Biotechnol 2015,25(6),946-950","journal-title":"J Microbiol Biotechnol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/jac\/dkv495","volume":"71","author":"Trinconi C.T.","year":"2016","unstructured":"Trinconi C.T.; Reim\u00e3o J.Q.; Coelho A.C.; Uliana S.R.B.; Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. J Antimicrob Chemother 2016,71(5),1314-1322","journal-title":"J Antimicrob Chemother"},{"key":"ref=18","first-page":"651","volume":"93","author":"El Arbi M.","year":"2011","unstructured":"El Arbi M.; Pigeon P.; Rkhis A.C.; Top S.; Rhouma A.; Rebai A.; Jaouen G.; Aifa S.; Antimicrobial effect of ferrocenyl diaryl butenes against olive plantlet diseases. J Plant Pathol 2011,93(3),651-657","journal-title":"J Plant Pathol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jorganchem.2010.09.015","volume":"696","author":"El Arbi M.","year":"2011","unstructured":"El Arbi M.; Pigeon P.; Top S.; Rhouma A.; Aifa S.; Rebai A.; Vessi\u00e8res A.; Plamont M-A.; Jaouen G.; Evaluation of bactericidal and fungicidal activity of ferrocenyl or phenyl derivatives in the diphenyl butene series. J Organomet Chem 2011,696(5),1038-1048","journal-title":"J Organomet Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ejmech.2014.02.037","volume":"76","author":"El Arbi M.","year":"2014","unstructured":"El Arbi M.; Th\u00e9olier J.; Pigeon P.; Jellali K.; Trigui F.; Top S.; Aifa S.; Fliss I.; Jaouen G.; Hammami R.; Antibacterial properties and mode of action of new triaryl butene citrate compounds. Eur J Med Chem 2014,76,408-413","journal-title":"Eur J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1039\/C5MD00568J","volume":"7","author":"El Arbi M.","year":"2016","unstructured":"El Arbi M.; Jall\u00e9li K.; Trigui F.; Pigeon P.; G\u00f6rmen M.; Top S.; Aifa S.; Fliss I.; Jaouen G.; Hammami R.; Efficacy of a novel ferrocenyl diaryl butene citrate compound as a biocide for preventing healthcare associated infections. Med Chem Comm 2016,7(5),948-954","journal-title":"Med Chem Comm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2174\/1389557517666170208142254","volume":"18","author":"Arbi M.E.","year":"2018","unstructured":"Arbi M.E.; Ketata E.; Neifar A.; Mihoubi W.; Gupta G.K.; Pigeon P.; Top S.; Gargouri A.; Jaouen G.; Aryl butenes active against K562 cells and lacking tyrosinase inhibitory activity as new leads in the treatment of leukemia. Mini Rev Med Chem 2018,18(15),1294-1301","journal-title":"Mini Rev Med Chem"},{"key":"ref=23","first-page":"1","volume":"508","author":"Jellali K.","year":"2013","unstructured":"Jellali K.; Pigeon P.; Trigui F.; Top S.; Aifa S.; Jaouen G.; El Arbi M.; Effect of the amino chain length and the transformation\ninto citric acid salts of aryldiphenyl-butenes and ferrocenyldiphenylbutenes\nbearing two dimethylaminoalkyl chains on their\nantimicrobial activities  SpringerPlus, 2 2013,508,1-9","journal-title":"SpringerPlus, 2"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jorganchem.2017.07.031","volume":"848","author":"Ketata E.","year":"2017","unstructured":"Ketata E.; Neifar A.; Mihoubi W.; Pigeon P.; Gouzi H.; Mallet J-M.; Top S.; Gupta G.K.; Jaouen G.; Gargouri A.; El Arbi M.; The inhibition of tyrosinase by some aryl butenes: A desired activity or a side effect to avoid. J Organomet Chem 2017,848,133-141","journal-title":"J Organomet Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1039\/c1nj20192a","volume":"35","author":"Pigeon P.","year":"2011","unstructured":"Pigeon P.; Top S.; Vessi\u00e8res A.; Huch\u00e9 M.; Gormen M.; El Arbi M.; Plamont M-A.; McGlinchey M.J.; Jaouen G.; A new series of ferrocifen derivatives, bearing two aminoalkyl chains, with strong antiproliferative effects on breast cancer cells. New J Chem 2011,35(10),2212-2218","journal-title":"New J Chem"},{"key":"ref=26","author":"Maryland R.C.","year":"1996","unstructured":"Maryland R.C.;  Guide for the care and use of laboratory animals Institute of Laboratory Animal Resources Commission on Life Sciences 1996","journal-title":"Guide for the care and use of laboratory animals Institute of Laboratory Animal Resources Commission on Life Sciences"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"Friedewald W.T.","year":"1972","unstructured":"Friedewald W.T.; Levy R.I.; Fredrickson D.S.; Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972,18(6),499-502","journal-title":"Clin Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0005-2736(99)00237-0","volume":"1464","author":"Cruz Silva M.M.","year":"2000","unstructured":"Cruz Silva M.M.; Madeira V.M.; Almeida L.M.; Cust\u00f3dio J.B.; Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure. Biochim Biophys Acta 2000,1464(1),49-61","journal-title":"Biochim Biophys Acta"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0887-2333(01)00079-0","volume":"15","author":"Cruz Silva M.M.","year":"2001","unstructured":"Cruz Silva M.M.; Madeira V.M.; Almeida L.M.; Cust\u00f3dio J.B.; Hydroxytamoxifen interaction with human erythrocyte membrane and induction of permeabilization and subsequent hemolysis. Toxicol In Vitro 2001,15(6),615-622","journal-title":"Toxicol In Vitro"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00000421-199910000-00022","volume":"22","author":"Yao J.C.","year":"1999","unstructured":"Yao J.C.; Thomakos N.; McLaughlin P.; Buchholz T.A.; Kudelka A.P.; Tamoxifen-induced thrombocytopenia. Am J Clin Oncol 1999,22(5),529-532","journal-title":"Am J Clin Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.2174\/092986709788803042","volume":"16","author":"Behjati S.","year":"2009","unstructured":"Behjati S.; Frank M.H.; The effects of tamoxifen on immunity. Curr Med Chem 2009,16(24),3076-3080","journal-title":"Curr Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/jnci\/85.16.1344","volume":"85","author":"Love R.R.","year":"1993","unstructured":"Love R.R.; Mamby C.C.; Feyzi J.M.; Tamoxifen-induced decreases in total cholesterol with 2 weeks of treatment. J Natl Cancer Inst 1993,85(16),1344-1345","journal-title":"J Natl Cancer Inst"},{"key":"ref=33","first-page":"36","volume":"53","author":"Hozumi Y.","year":"2000","unstructured":"Hozumi Y.; Kawano M.; Hakamata Y.; Miyata M.; Jordan V.C.; Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies. Horm Res 2000,53(1),36-39","journal-title":"Horm Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/hep.23813","volume":"52","author":"Cole L.K.","year":"2010","unstructured":"Cole L.K.; Jacobs R.L.; Vance D.E.; Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 2010,52(4),1258-1265","journal-title":"Hepatology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000358752","volume":"9","author":"Lin C.","year":"2014","unstructured":"Lin C.; Chen L-S.; Kuo S-J.; Chen D-R.; Adjuvant tamoxifen influences the lipid profile in breast cancer patients. Breast Care (Basel) 2014,9(1),35-39","journal-title":"Breast Care (Basel)"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1194\/jlr.M600148-JLR200","volume":"47","author":"Gudbrandsen O.A.","year":"2006","unstructured":"Gudbrandsen O.A.; Rost T.H.; Berge R.K.; Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res 2006,47(10),2223-2232","journal-title":"J Lipid Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/01.CIR.95.6.1542","volume":"95","author":"Reckless J.","year":"1997","unstructured":"Reckless J.; Metcalfe J.C.; Grainger D.J.; Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997,95(6),1542-1548","journal-title":"Circulation"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185079\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T11:50:10Z","timestamp":1618401010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185079\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":37,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020,11,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200819145526","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}